This study evaluates the use of a novel non-ionizing and noninvasive ultrasound elastography technique called harmonic motion imaging (HMI) in predicting response to neoadjuvant chemotherapy in women with breast cancer. HMI uses a push pulse to vibrate the target tissue. Currently, there is no optimum technique to predict the early clinical outcome of the NACT in breast cancer patients. Information gained from this study may help researchers learn whether this novel technique can make a difference in the current practice of early prediction of breast cancer response to neoadjuvant therapy by offering a non-ionizing, noninvasive, highly accurate and cost efficient complementary method to existing screening and detection techniques.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04824027.
Locations matching your search criteria
United States
New York
New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterStatus: Active
Contact: Elisa E. Konofagou
Phone: 212-342-0863
PRIMARY OBJECTIVE:
I. To compare the changes in the measurements provided by HMI and pathological response rate, between baseline, during treatment and end of the treatment to assess whether HMI can early predict the tumor response to neoadjuvant therapy.
OUTLINE:
During neoadjuvant systemic treatment, patients undergo HMI over 30 minutes at baseline, 4 weeks into therapy (short-interval follow-up), and at the completion of systemic therapy. Patients also undergo breast ultrasound on the same as HMI assessment per standard of care.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Principal InvestigatorElisa E. Konofagou
